NO20021122L - Sammensetninger og terapeutiske fremgangsmater som involverer isoflavoner og deres analoger - Google Patents

Sammensetninger og terapeutiske fremgangsmater som involverer isoflavoner og deres analoger

Info

Publication number
NO20021122L
NO20021122L NO20021122A NO20021122A NO20021122L NO 20021122 L NO20021122 L NO 20021122L NO 20021122 A NO20021122 A NO 20021122A NO 20021122 A NO20021122 A NO 20021122A NO 20021122 L NO20021122 L NO 20021122L
Authority
NO
Norway
Prior art keywords
analogs
compositions
therapeutic methods
methods involving
isoflavones
Prior art date
Application number
NO20021122A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021122D0 (no
Inventor
Andrew Heaton
Naresh Kumar
Edmund Graham Kelly
Alan James Husband
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of NO20021122D0 publication Critical patent/NO20021122D0/no
Publication of NO20021122L publication Critical patent/NO20021122L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
NO20021122A 1999-09-06 2002-03-06 Sammensetninger og terapeutiske fremgangsmater som involverer isoflavoner og deres analoger NO20021122L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ2661A AUPQ266199A0 (en) 1999-09-06 1999-09-06 Compositions and therapeutic methods involving isoflavones and analogues thereof
PCT/AU2000/001056 WO2001017986A1 (en) 1999-09-06 2000-09-06 Compositions and therapeutic methods involving isoflavones and analogues thereof

Publications (2)

Publication Number Publication Date
NO20021122D0 NO20021122D0 (no) 2002-03-06
NO20021122L true NO20021122L (no) 2002-03-26

Family

ID=3816831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021122A NO20021122L (no) 1999-09-06 2002-03-06 Sammensetninger og terapeutiske fremgangsmater som involverer isoflavoner og deres analoger

Country Status (18)

Country Link
US (3) US7488494B2 (de)
EP (2) EP1721903A1 (de)
JP (1) JP2003508526A (de)
CN (2) CN1372555A (de)
AT (1) ATE334978T1 (de)
AU (2) AUPQ266199A0 (de)
BR (1) BR0013777A (de)
CA (1) CA2384099A1 (de)
CZ (1) CZ20021077A3 (de)
DE (1) DE60029797D1 (de)
HK (1) HK1048993A1 (de)
HU (1) HUP0202570A3 (de)
IL (2) IL148061A0 (de)
NO (1) NO20021122L (de)
NZ (2) NZ529085A (de)
TR (1) TR200200581T2 (de)
WO (1) WO2001017986A1 (de)
ZA (1) ZA200200835B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40792E1 (en) * 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6340703B1 (en) * 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
EP1368024A4 (de) * 2001-03-16 2009-03-18 Novogen Res Pty Ltd Behandlung von restenose
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
JP2012149096A (ja) * 2001-12-18 2012-08-09 Daicho Kikaku:Kk 抗炎症剤
EP1503751A4 (de) * 2002-04-09 2007-08-01 Novogen Res Pty Ltd Therapeutische verfahren und zusammensetzungen mit isoflav-3-en und isoflavan-strukturen
WO2004014886A1 (en) * 2002-08-07 2004-02-19 University Of Mississippi Antigiardial agents and use thereof
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
JP2007525485A (ja) * 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
ATE532777T1 (de) 2004-09-21 2011-11-15 Marshall Edwards Inc Substituierte chromanderivate, medikamente und anwendungen in der therapie
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006032086A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy
CN101203219B (zh) * 2005-03-24 2011-06-15 诺沃根研究控股有限公司 消炎用药程式
US20140107051A1 (en) * 2005-09-21 2014-04-17 Instytut Farmaceutyczny Isoflavones for treating mucopolysaccharidoses
US7696363B2 (en) * 2005-12-02 2010-04-13 Yasoo Health Inc. Preparation of flavonoid compounds
US20070203227A1 (en) * 2006-02-24 2007-08-30 Herman Adlercreutz Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
EP2160385A4 (de) * 2007-06-29 2010-10-27 Novogen Res Pty Ltd 2-substituierte isoflavonoid-verbindungen sowie medikamente daraus und anwendungen davon
WO2009049214A2 (en) * 2007-10-12 2009-04-16 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2334296A4 (de) * 2008-08-29 2012-04-25 Novogen Res Pty Ltd Immunmodulierende aktivitäten
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
TWI472525B (zh) 2008-12-05 2015-02-11 Otsuka Pharma Co Ltd 喹啉酮化合物及藥學組成物
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
ITRM20130366A1 (it) * 2013-06-25 2014-12-26 Univ Roma La Sapienza Multitarget hedgehog pathway inhibitors and uses thereof
CN107427003B (zh) 2015-02-02 2023-01-31 梅制药公司 联合治疗
EP3439642A4 (de) * 2016-04-06 2019-11-13 Noxopharm Limited Verbesserungen an der strahlentherapie
AU2017247008B2 (en) 2016-04-06 2022-04-07 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CN106977500A (zh) * 2017-04-17 2017-07-25 牡丹江医学院 一种用于治疗脑梗塞的药物及其制备方法
EP4125870A1 (de) 2020-03-30 2023-02-08 Noxopharm Limited Verfahren zur behandlung von entzündungen im zusammenhang mit infektionen
CN112716934A (zh) * 2021-01-27 2021-04-30 华中科技大学同济医学院附属协和医院 7-甲氧基异黄酮在内皮炎症中的应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518002C3 (de) 1965-01-02 1975-01-23 Merck Patent Gmbh, 6100 Darmstadt Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel
DE1543749A1 (de) 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
JPS54734B2 (de) 1973-05-14 1979-01-16
US3973608A (en) 1973-08-01 1976-08-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Microbial production of certain isoflavones
JPS576427B2 (de) 1974-01-25 1982-02-04
HU168753B (de) 1974-05-03 1976-07-28
JPS50160483A (de) 1974-06-19 1975-12-25
GB1495189A (en) * 1975-09-12 1977-12-14 Pfizer Ltd 4-oxo-4h-benzopyran derivatives and process for their preparation
DE2643800C2 (de) 1976-09-29 1986-10-30 Fritz Werner Industrie-Ausrüstungen GmbH, 6222 Geisenheim Verfahren zur Herstellung von Xylose durch enzymatische Hydrolyse von Xylanen
US4264509A (en) 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4157984A (en) * 1977-06-08 1979-06-12 Z-L Limited Antioxidants, antioxidant compositions and methods of preparing and using same
SU907060A1 (ru) 1979-02-07 1982-02-23 Всесоюзный Научно-Исследовательский Биотехнический Институт Способ получени розового масла
US4390559A (en) 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US4366082A (en) 1979-04-11 1982-12-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
JPS5933232A (ja) 1982-08-19 1984-02-23 Tokiwa Kanpou Seiyaku:Kk マメ科植物からサポニン類およびフラボン類の分離方法
JPS59199630A (ja) 1983-04-26 1984-11-12 Takeda Chem Ind Ltd 卵巣機能低下症治療剤
JPS6048924A (ja) 1983-08-24 1985-03-16 Takeda Chem Ind Ltd 骨粗鬆症治療剤
JPS6054379A (ja) 1983-09-05 1985-03-28 Takeda Chem Ind Ltd 新規４ｈ−１−ベンゾピラン−４−オン誘導体，その製法および用途
JPS61247396A (ja) 1985-04-24 1986-11-04 Yamanouchi Pharmaceut Co Ltd ゲニステインの製造法
JPS61246124A (ja) 1985-04-24 1986-11-01 Yamanouchi Pharmaceut Co Ltd 制癌剤
JPS62106016A (ja) 1985-11-01 1987-05-16 Yamanouchi Pharmaceut Co Ltd 免疫抑制剤
JPS62106017A (ja) 1985-11-01 1987-05-16 Yamanouchi Pharmaceut Co Ltd 抗腫瘍剤
JPS62126186A (ja) 1985-11-28 1987-06-08 Tsumura Juntendo Inc イソフラボン誘導体含有溶液の製造方法
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
JPS6442427A (en) 1987-08-10 1989-02-14 Tsumura & Co Sialidase inhibitor
JPH0832632B2 (ja) * 1988-03-08 1996-03-29 株式会社太田胃散 尿素窒素代謝改善剤
JPH0714927B2 (ja) 1988-04-06 1995-02-22 キッコーマン株式会社 イソフラボン化合物の製造法
JPH0267218A (ja) 1988-08-31 1990-03-07 Nagakura Seiyaku Kk ウイルス・ゲノム不活化剤
JPH0269165A (ja) 1988-09-02 1990-03-08 Mitsugi Ohashi 癌抑制食品
JPH02124883A (ja) 1988-11-04 1990-05-14 Kitasato Inst:The 抗酸化作用を有するイソフラボン誘導体およびその製造法
JP2753719B2 (ja) 1988-12-15 1998-05-20 日本油脂株式会社 リポソーム製剤の製造法
JPH0347049A (ja) 1989-03-09 1991-02-28 Sanyu:Kk 豆腐廃液ゆからの食品素材及び健康飲料の製造方法
CH679544A5 (de) * 1989-09-12 1992-03-13 Nestle Sa
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
CH679584A5 (de) 1989-11-10 1992-03-13 Nestle Sa
IT1241079B (it) 1990-03-23 1993-12-29 Chiesi Farma Spa Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
DE69006502T2 (de) 1990-04-06 1994-05-19 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., Budapest Verbessertes verfahren zur darstellung substituierter isoflavonderivate.
GB2261671B (en) 1991-11-16 1996-07-03 Gb Biotech Gel production from plant matter
JPH05170756A (ja) 1991-12-20 1993-07-09 Kikkoman Corp イソフラボン化合物の製造法
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
FR2693724B1 (fr) * 1992-07-17 1994-10-07 Lipha Utilisation de composés benzopyraniques ou benzothiopyraniques pour l'induction de l'expression des gènes de la nodulation des bactéries du genre Rhizobium associées aux légumineuses.
JPH0686682A (ja) 1992-07-23 1994-03-29 Kobe Steel Ltd ４’，７，８−トリヒドロキシイソフラボンの製造方法
JPH0640876A (ja) 1992-07-23 1994-02-15 Kobe Steel Ltd 紫外線障害防御外用剤
JPH0640909A (ja) 1992-07-23 1994-02-15 Kobe Steel Ltd スーパーオキシド・ディスムターゼ様活性剤
EP0693927A4 (de) 1993-04-16 1997-05-28 Univ Tufts Med Verfahren zur behandlung menopausaler und prämentrueller symptome
JPH06321752A (ja) 1993-05-07 1994-11-22 Kao Corp 美白剤
HUT68558A (en) 1993-07-20 1995-06-28 Chinoin Gyogyszer Es Vegyeszet Method for preparing isoflavon derivatives
US5320949A (en) 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
BR9407822A (pt) 1993-10-12 1997-05-06 Protein Tech Int Processo para produção de um soro de leite coalhado de proteina vegetal enriquecido com aglucono isoflavona soro de leite coalhado enriquecido com aglucono isoflavona proteina de soro de leite coalhado enriquecido com aglucono isoflavona e processo para a recuperação em uma proteina de leite coalhado de pelo mones 50% de uma isoflavona de um material de proteina vegetal
CA2173743A1 (en) 1993-10-12 1995-04-20 Jerome L. Shen An aglucone isoflavone enriched vegetable protein extract and isolate and process for producing
JP3078694B2 (ja) 1993-12-17 2000-08-21 キッコーマン株式会社 ゲニステインの製造法
IL112061A (en) 1994-01-13 1999-10-28 Bristol Myers Squibb Co Methods for the preparation of taxanes
US6369103B1 (en) 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
US5506211A (en) 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US5424331A (en) 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
US5547866A (en) 1994-07-20 1996-08-20 The Regents Of The University Of California Taxane production in haploid-derived cell cultures
DE4432947C2 (de) * 1994-09-16 1998-04-09 New Standard Gmbh Mittel zur Behandlung der Haut und seine Verwendung
AU3689095A (en) 1994-10-03 1996-04-26 Schouten Industries B.V. Food and health products
US5516528A (en) 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
US5523087A (en) 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
US5569459A (en) 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5679806A (en) 1995-02-24 1997-10-21 Hauser, Inc. Process for the isolation and purification of isoflavones
JPH08283283A (ja) 1995-04-14 1996-10-29 Kikkoman Corp マロニルイソフラボン配糖体及び該物質からイソフラボン配糖体又はイソフラボンアグリコンを取得する方法
US5639785A (en) 1995-06-07 1997-06-17 Global Pharma, Ltd. Methods for the treatment of baldness and gray hair using isoflavonoid derivatives
WO1996041800A1 (en) 1995-06-12 1996-12-27 Chavunduka, Gordon, Lloyd Isolation of naturally occurring isoflavanone and some clinical uses thereof
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
JPH0967362A (ja) 1995-09-01 1997-03-11 Sankyo Co Ltd ５α−還元酵素阻害剤ビスイソフラボン類
US6261565B1 (en) 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US5702752A (en) 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US5821361A (en) 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
JPH1059956A (ja) 1996-08-22 1998-03-03 Kikkoman Corp 新規イソフラボン誘導体及びその製造法
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5726034A (en) 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US5804234A (en) 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US6146668A (en) 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
WO1998048790A1 (en) * 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
AUPO644897A0 (en) 1997-04-28 1997-05-22 Novogen Inc Preparation of isoflavones from legumes
US6340703B1 (en) 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
US6083526A (en) 1997-05-22 2000-07-04 Gorbach; Sherwood L. Use of isoflavonoids in the treatment or prevention of postpartum depression
US6060070A (en) 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
TR200000562T2 (tr) 1997-08-29 2000-08-21 Pfizer Products Inc. Amlodifin ve bir statin bileşiği içeren bileşim terapisi
US5855892A (en) 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5942539A (en) 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
FR2769502B1 (fr) 1997-10-14 2000-04-14 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.)
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AU2183899A (en) 1998-01-27 1999-08-09 Shionogi & Co., Ltd. Isoflavane derivatives and immunopotentiating compositions containing the same
US6004558A (en) 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
AUPP198798A0 (en) 1998-02-25 1998-03-19 Novogen Research Pty Ltd Compositions comprising extracts of isoflavone-containing plants and anti-cancer modalities involving the same
US6132795A (en) 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
CN1293565A (zh) 1998-03-16 2001-05-02 宝洁公司 调节皮肤外观的组合物
AUPP260798A0 (en) 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
KR20000001793A (ko) * 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
FR2781154B1 (fr) * 1998-07-15 2001-09-07 Lafon Labor Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
AU5440799A (en) 1998-09-17 2000-04-10 Guido Schnyder Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty
AUPP868599A0 (en) * 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
US6413546B1 (en) 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
JP2002542187A (ja) * 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
AUPQ008399A0 (en) 1999-04-28 1999-05-27 Novogen Research Pty Ltd Cariovascular applications
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites

Also Published As

Publication number Publication date
EP1210341A4 (de) 2003-06-11
CA2384099A1 (en) 2001-03-15
CZ20021077A3 (cs) 2002-08-14
HK1048993A1 (zh) 2003-04-25
US20060106220A1 (en) 2006-05-18
NZ529085A (en) 2005-08-26
IL148061A0 (en) 2002-09-12
AUPQ266199A0 (en) 1999-09-30
NZ539819A (en) 2006-12-22
HUP0202570A1 (hu) 2002-11-28
EP1210341B1 (de) 2006-08-02
EP1210341A1 (de) 2002-06-05
TR200200581T2 (tr) 2002-06-21
US20040147551A1 (en) 2004-07-29
BR0013777A (pt) 2002-05-07
AU7261700A (en) 2001-04-10
ZA200200835B (en) 2003-03-26
DE60029797D1 (de) 2006-09-14
HUP0202570A3 (en) 2005-01-28
WO2001017986A1 (en) 2001-03-15
JP2003508526A (ja) 2003-03-04
ATE334978T1 (de) 2006-08-15
EP1721903A1 (de) 2006-11-15
NO20021122D0 (no) 2002-03-06
US7488494B2 (en) 2009-02-10
IL193332A0 (en) 2009-05-04
US20080014249A1 (en) 2008-01-17
CN1372555A (zh) 2002-10-02
CN1680358A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
NO20021122D0 (no) Sammensetninger og terapeutiske fremgangsmåter som involverer isoflavoner og deres analoger
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
NO20020687L (no) 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20025150L (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20015477D0 (no) 4,5,6,7-tetrahydroindazol-derivater som anti-tumor midler
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
NO20040210L (no) Fenylacetamido-tiazolderivater, fremgangsmate for deres fremstilling og deres anvendelse som antitumormidler
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
IS6677A (is) Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningarsem innihalda þær
NO20034527L (no) 3,7-diazabicyklo(3,3,1) formuleringer som antiarytmiforbindelser
DE69830577D1 (de) Halo-alkoxycarbonylverbindungen
DK1307445T3 (da) Benzofuranderivater og deres anvendelse som antibakterielle midler
SI1368358T1 (sl) Izoksazolinski derivati kot antidepresivi
BR0213673B1 (pt) Composição fungicida sinérgica, método de controle e produto
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO20014753D0 (no) C(10)-karbonatsubstituerte taksaner som antitumormidler
NO20034528D0 (no) 3,7-diazabicyklo(3,3,1) formuleringer som antiarytmiforbindelser
NO20030820D0 (no) Anvendelse av vitamin D derivater som benresorpsjons inhibitorer
DK1278759T3 (da) Bis-(N,N'-bis-(2-halogenethyl)amino)phoshoramidater som antitumormidler
DK1297835T3 (da) Benzo[b]pyrano[3,2-h]acridin-7-on-forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse
DK1458721T3 (da) 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indol-1-carbox-amidderivater, deres fremstilling og terapeutisk anvendelse
ITMI20022408A1 (it) Uso odontostomatologico di fito-complessi a base di radici di rabarbaro (specie appartenenti al genere rheum) e foglie di spinaci (spinacia oleracea l.).

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application